Infertility (IVF Patients)NCT07771283
Purpose to Evaluate the Effectiveness of the Superovulation Stimulation Protocol Using Human Chorionic Gonadotropin (hCG) by Demonstrating Its Equivalence to Standard Controlled Ovarian Stimulation Protocols in Terms of Oocytes Retrieved, Blastulation While Maintaining an Economic Advantage
A study testing Human Chorionic Gonadotropin (hCG), GnRH antagonist and Dual trigger (human chorionic gonadotropin plus GnRH-agonist) in people with Infertility (IVF Patients) and Infertility Assisted Reproductive Technology, run by LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro at 3 sites in 2 countries.
Trial summary
This study evaluates a more affordable medication protocol for ovarian stimulation during in vitro fertilization (IVF). Standard IVF protocols use medications called gonadotropins to stimulate the ovaries to produce multiple eggs, but these medications can be very expensive and create a barrier to treatment. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Infertility (IVF Patients), Infertility Assisted Reproductive Technology, Infertile Patients
- What is being tested?
- Human Chorionic Gonadotropin (hCG), GnRH antagonist and Dual trigger (human chorionic gonadotropin plus GnRH-agonist)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 360 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 17 Aug 2026to 1 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women of reproductive age between 18 and 40 years.
- Clinical indications for the induction of superovulation (undergoing ART/IVF programs).
- Patients with all variants of ovarian reserve.
- Body Mass Index (BMI) up to 35 kg/m².
- Provision of informed consent to participate in the research study.
Who cannot join
- Presence of ovarian endometriomas.
- History of severe Ovarian Hyperstimulation Syndrome (OHSS) in previous cycles.
- Presence of severe endocrine disorders.
- History or presence of oncological diseases.
- Any medical contraindications to hormonal stimulation.
- Severe male factor infertility (specifically cryptozoospermia)
Trial locations and contacts
3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
3 sites in 2 countries
Ukraine2 sites
LTD "Yuzko" Yuzko Medical Center
Chernivtsi
LTD "EKODNIPRO" Medical Centre "Medical Plaza"
Dnipro
About this study
Official title: Prospective Randomized Single-Blind Study of the Effectiveness of the Superovulation Stimulation Protocol Using hCG Compared to Standard Protocols With Different Gonadotropin Doses in In Vitro Fertilization Programs
This study evaluates a more affordable medication protocol for ovarian stimulation during in vitro fertilization (IVF). Standard IVF protocols use medications called gonadotropins to stimulate the ovaries to produce multiple eggs, but these medications can be very expensive and create a barrier to treatment. This clinical trial tests whether substituting a significant portion of these standard medications with human chorionic gonadotropin (hCG) is just as effective. Researchers will compare the number and quality of eggs and embryos produced by women using the experimental hCG protocol versus those using the standard gonadotropin protocol. The main goal is to determine if the hCG method can provide similar clinical outcomes and safety profiles while significantly reducing the overall financial cost of IVF treatment.
Read the detailed description
Ovarian stimulation is a critical phase in assisted reproductive technologies (ART), but the high cost of recombinant gonadotropins remains a significant barrier to the accessibility of care for many patients. Human chorionic gonadotropin (hCG), due to its structural similarity to luteinizing hormone (LH), binds to LH/hCG receptors and can effectively support steroidogenesis and folliculogenesis when administered in sub-trigger doses. This prospective, randomized, single-blind trial is designed as a non-inferiority study to demonstrate that an hCG-based stimulation protocol is equivalent to standard controlled ovarian stimulation. While standard protocols rely on the continuous administration of follicle-stimulating hormone (FSH) or FSH/LH, the experimental protocol introduces 200 IU of hCG (without FSH) to replace standard gonadotropins once the main cohort of follicles reaches 11 to 12 millimeters in size. Both treatment arms will utilize a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation, followed by a dual trigger for final oocyte maturation. To minimize bias and ensure objective results, the embryologists evaluating oocyte morphology, fertilization rates, and blastocyst development will be blinded to the treatment arm assignments. If moderate or severe ovarian hyperstimulation syndrome (OHSS) is suspected in the experimental group, the protocol incorporates safety measures, including switching to a GnRH agonist trigger and utilizing a "freeze-all" strategy. By thoroughly comparing these methods through both intention-to-treat (ITT) and per-protocol (PP) analyses, researchers aim to validate an individualized treatment approach. Proving the non-inferiority of this alternative protocol could potentially reduce the medication cost of an IVF cycle by 30 to 60 percent, providing clinicians with a flexible, cost-effective tool without compromising clinical efficacy or patient safety.
- Conditions
- Infertility (IVF Patients), Infertility Assisted Reproductive Technology, Infertile Patients, Infertility Drugs, Infertile Women Undergoing IVF or ICSI, Infertility
- Being tested
- Human Chorionic Gonadotropin (hCG), GnRH antagonist, Dual trigger (human chorionic gonadotropin plus GnRH-agonist), Gonadotropins (FSH or FSH/LH)
- Keywords
- Human Chorionic Gonadotropin (hCG), Infertility, Female Infertility, Gonadotropins, Assisted Reproductive Technology (ART), Controlled Ovarian Stimulation (COS), Ovarian Stimulation
- Medical subject headings
- Infertility, Infertility, Female
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Human Chorionic Gonadotropin (hCG)Drug
Administered in sub-trigger doses of 200 IU (without FSH) as a substitute for LH activity and to support folliculogenesis
GnRH antagonistDrug
Administered starting on the 6th day of stimulation as part of a fixed antagonist protocol
Dual trigger (human chorionic gonadotropin plus GnRH-agonist)Drug
Also called GnRH-agonist in case high risk of OHSS
Administered to induce final oocyte maturation before retrieval
Gonadotropins (FSH or FSH/LH)Drug
Standard follicle-stimulating hormone (FSH) or FSH/LH preparations administered continuously at doses ranging from 100 to 225 IU/day.
Gonadotropins (FSH or FSH/LH)Drug
Standard follicle-stimulating hormone (FSH) or FSH/LH preparations administered continuously at doses ranging from 100 to 225 IU/day before main cohort of follicles reach size 11-12mm
| Study group | Role | What they receive |
|---|---|---|
| hCG Protocol | Experimental | atients in this group undergo ovarian stimulation where human chorionic gonadotropin (hCG) replaces standard gonadotropins (or a significant portion of them) once the main cohort of follicles reaches 11-12 mm in size. This arm utilizes a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation and a dual trigger for final maturation. Receives: Drug: Human Chorionic Gonadotropin (hCG); Drug: GnRH antagonist; Drug: Dual trigger (human chorionic gonadotropin plus GnRH-agonist); Drug: Gonadotropins (FSH or FSH/LH) |
| Standard Protocol | Active comparator | Patients in this group undergo standard controlled ovarian stimulation using continuous administration of gonadotropins. This arm also utilizes a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation and a dual trigger for final maturation Receives: Drug: GnRH antagonist; Drug: Dual trigger (human chorionic gonadotropin plus GnRH-agonist); Drug: Gonadotropins (FSH or FSH/LH) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of oocytes retrieved (oocyte yield)
The total count of oocytes retrieved following the controlled ovarian stimulation protocol
Measured: Day of oocyte retrieval (typically 34-36 hours after trigger administration)
Proportion of Mature Oocytes (MII Rate)
Description: The percentage of retrieved oocytes that have reached the Metaphase II (MII) stage, evaluated according to the standardized ESHRE/ALPHA (Istanbul Consensus, 2025 update) criteria
Measured: Day of oocyte retrieval
Fertilization Rate
The percentage of mature oocytes (MII) that are successfully fertilized.
Measured: Day 1 following oocyte retrieval
Embryo Quality
The percentage of good quality cleavage-stage embryos and good quality blastocysts, assessed according to the standardized ESHRE/ALPHA (Istanbul Consensus, 2025 update) criteria.
Measured: Day 3 and Day 5 following oocyte retrieval
Total Dose of Gonadotropins/hCG
The total cumulative dose in International Units (IU) of gonadotropins or hCG administered throughout the entire stimulation cycle
Measured: From Day 1 of stimulation up to the day of trigger administration (approximately 10-14 days)
Secondary outcomes (6)
Clinical Pregnancy Rate
The percentage of patients who achieve a clinical pregnancy following embryo transfer
Measured: Approximately 4 to 6 weeks following embryo transfer
Live Birth Rate
The percentage of patients who achieve a live birth
Measured: Approximately 9 to 10 months following embryo transfer
Incidence of Ovarian Hyperstimulation Syndrome (OHSS)
The frequency of moderate and severe OHSS cases, classified according to RCOG/ESHRE criteria
Measured: From the day of trigger administration through the luteal phase/early pregnancy
Average Duration of Stimulation
The total number of days the stimulation medications were administered.
Measured: From Day 1 of stimulation up to the day of trigger administration (approximately 10-14 days)
Endometrial Thickness
The thickness of the endometrium measured in millimeters (mm) via ultrasound
Measured: On the day of trigger administration
Cost of Stimulation Protocol per Cycle
An economic evaluation calculating the total cost of all medications consumed during the stimulation cycle, initially recorded in UAH and converted to USD.
Measured: At the completion of the stimulation protocol (day of trigger)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start17 Aug 2026
- Primary completion1 Feb 2028 (estimated)
- Study completion1 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Infertility (IVF Patients)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective, randomized, parallel-group, non-inferiority trial. Participants are allocated to one of two treatment groups (Group A or Group B) using block randomization (block size of 6) stratified by the participating institution. Allocation concealment is ensured through the use of Sequentially Numbered Opaque Sealed Envelopes (SNOSE). Due to the distinct differences in medication administration regimens between the two groups, the study is open-label for the patients and the treating physicians. However, to minimize bias, the study employs a single-blind outcome assessment design. The embryologists responsible for evaluating oocyte and embryo quality, as well as the personnel assessing clinical pregnancy and live birth rates, will be completely blinded to the participants' assigned treatment groups.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 360 participants (estimated)
Sponsor and investigators
- Lead sponsor
- LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro
- Sponsor type
- University, hospital or other
- Collaborators
- LTD "Yuzko"
- Responsible party
- Principal investigator, Oleksandr Plyh, LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro
- Investigators
- Oleksandr O. Plyh, MD, Principal investigator, LTD "EKODNIPRO"
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07771283
- Sponsor's protocol ID
- 2
- Status last verified
- Aug 2026
- First submitted
- 10 Aug 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) that underlie the results reported in the final published article will be shared. This includes data collected for the primary and secondary endpoints, after appropriate anonymization to ensure strict compliance with GDPR and Ukrainian data protection laws.
Publications
Huong NTL, Thuy TT, Anh PTT, Long HB, Thang LD, Ngoc VT, Do LQ, Duy NXA, Hanh BT, Loi DV, Hoang L. Effects of 100 IU versus 150 IU hCG supplementation on oocyte and embryo quality in patients aged >/= 35 years: a propensity score-matched analysis. Int J Med Sci. 2025 Jan 27;22(4):982-989. doi: 10.7150/ijms.106965. eCollection 2025.
PubMed 39991766Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study. Hum Reprod. 2009 Nov;24(11):2910-6. doi: 10.1093/humrep/dep253. Epub 2009 Jul 17.
PubMed 19617207Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005 Aug;84(2):394-401. doi: 10.1016/j.fertnstert.2005.02.036.
PubMed 16084880Lin H, Huang X, Zhao Y, Wang Y, Wang S, Hong F, Pan M, Liu L. Low-dose human chorionic gonadotropin supplementation initiated at the onset of ovarian stimulation can improve oocyte quality without impairing endometrial receptivity: Case series. Medicine (Baltimore). 2022 Dec 2;101(48):e32175. doi: 10.1097/MD.0000000000032175.
PubMed 36482630
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Randomized Single-Blind Study of the Effectiveness of the Superovulation Stimulation Protocol Using hCG Compared to Standard Protocols With Different Gonadotropin Doses in In Vitro Fertilization Programs
- ClinicalTrials.gov ID
- NCT07771283
- Acronym / sponsor ID
- 2
- Conditions
- Infertility (IVF Patients), Infertility Assisted Reproductive Technology, Infertile Patients, Infertility Drugs, Infertile Women Undergoing IVF or ICSI, Infertility
- Keywords
- Human Chorionic Gonadotropin (hCG), Infertility, Female Infertility, Gonadotropins, Assisted Reproductive Technology (ART), Controlled Ovarian Stimulation (COS), Ovarian Stimulation
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 360 participants (estimated)
- Lead sponsor
- LTD "EKODNIPRO", Medical centre Medical Plaza DniproUniversity, hospital or other
- Collaborators
- LTD "Yuzko"
- Study start
- 17 Aug 2026 (actual)
- Primary completion
- 1 Feb 2028 (estimated)
- Study completion
- 1 May 2028 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates a more affordable medication protocol for ovarian stimulation during in vitro fertilization (IVF). Standard IVF protocols use medications called gonadotropins to stimulate the ovaries to produce multiple eggs, but these medications can be very expensive and create a barrier to treatment. This clinical trial tests whether substituting a significant portion of these standard medications with human chorionic gonadotropin (hCG) is just as effective. Researchers will compare the number and quality of eggs and embryos produced by women using the experimental hCG protocol versus those using the standard gonadotropin protocol. The main goal is to determine if the hCG method can provide similar clinical outcomes and safety profiles while significantly reducing the overall financial cost of IVF treatment.
Detailed description
Ovarian stimulation is a critical phase in assisted reproductive technologies (ART), but the high cost of recombinant gonadotropins remains a significant barrier to the accessibility of care for many patients. Human chorionic gonadotropin (hCG), due to its structural similarity to luteinizing hormone (LH), binds to LH/hCG receptors and can effectively support steroidogenesis and folliculogenesis when administered in sub-trigger doses. This prospective, randomized, single-blind trial is designed as a non-inferiority study to demonstrate that an hCG-based stimulation protocol is equivalent to standard controlled ovarian stimulation. While standard protocols rely on the continuous administration of follicle-stimulating hormone (FSH) or FSH/LH, the experimental protocol introduces 200 IU of hCG (without FSH) to replace standard gonadotropins once the main cohort of follicles reaches 11 to 12 millimeters in size. Both treatment arms will utilize a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation, followed by a dual trigger for final oocyte maturation. To minimize bias and ensure objective results, the embryologists evaluating oocyte morphology, fertilization rates, and blastocyst development will be blinded to the treatment arm assignments. If moderate or severe ovarian hyperstimulation syndrome (OHSS) is suspected in the experimental group, the protocol incorporates safety measures, including switching to a GnRH agonist trigger and utilizing a "freeze-all" strategy. By thoroughly comparing these methods through both intention-to-treat (ITT) and per-protocol (PP) analyses, researchers aim to validate an individualized treatment approach. Proving the non-inferiority of this alternative protocol could potentially reduce the medication cost of an IVF cycle by 30 to 60 percent, providing clinicians with a flexible, cost-effective tool without compromising clinical efficacy or patient safety.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This is a prospective, randomized, parallel-group, non-inferiority trial. Participants are allocated to one of two treatment groups (Group A or Group B) using block randomization (block size of 6) stratified by the participating institution. Allocation concealment is ensured through the use of Sequentially Numbered Opaque Sealed Envelopes (SNOSE). Due to the distinct differences in medication administration regimens between the two groups, the study is open-label for the patients and the treating physicians. However, to minimize bias, the study employs a single-blind outcome assessment design. The embryologists responsible for evaluating oocyte and embryo quality, as well as the personnel assessing clinical pregnancy and live birth rates, will be completely blinded to the participants' assigned treatment groups.
| Arm | Type | Receives |
|---|---|---|
| hCG Protocol | Experimental | Drug: Human Chorionic Gonadotropin (hCG), Drug: GnRH antagonist, Drug: Dual trigger (human chorionic gonadotropin plus GnRH-agonist), Drug: Gonadotropins (FSH or FSH/LH)atients in this group undergo ovarian stimulation where human chorionic gonadotropin (hCG) replaces standard gonadotropins (or a significant portion of them) once the main cohort of follicles reaches 11-12 mm in size. This arm utilizes a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation and a dual trigger for final maturation. |
| Standard Protocol | Active comparator | Drug: GnRH antagonist, Drug: Dual trigger (human chorionic gonadotropin plus GnRH-agonist), Drug: Gonadotropins (FSH or FSH/LH)Patients in this group undergo standard controlled ovarian stimulation using continuous administration of gonadotropins. This arm also utilizes a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation and a dual trigger for final maturation |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Women of reproductive age between 18 and 40 years.
- Clinical indications for the induction of superovulation (undergoing ART/IVF programs).
- Patients with all variants of ovarian reserve.
- Body Mass Index (BMI) up to 35 kg/m².
- Provision of informed consent to participate in the research study.
Key exclusion criteria (6 listed)
- Presence of ovarian endometriomas.
- History of severe Ovarian Hyperstimulation Syndrome (OHSS) in previous cycles.
- Presence of severe endocrine disorders.
- History or presence of oncological diseases.
- Any medical contraindications to hormonal stimulation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Human Chorionic Gonadotropin (hCG)Administered in sub-trigger doses of 200 IU (without FSH) as a substitute for LH activity and to support folliculogenesis | Drug | hCG Protocol |
| GnRH antagonistAdministered starting on the 6th day of stimulation as part of a fixed antagonist protocol | Drug | Standard Protocol, hCG Protocol |
| Dual trigger (human chorionic gonadotropin plus GnRH-agonist)Also: GnRH-agonist in case high risk of OHSSAdministered to induce final oocyte maturation before retrieval | Drug | Standard Protocol, hCG Protocol |
| Gonadotropins (FSH or FSH/LH)Standard follicle-stimulating hormone (FSH) or FSH/LH preparations administered continuously at doses ranging from 100 to 225 IU/day. | Drug | Standard Protocol |
| Gonadotropins (FSH or FSH/LH)Standard follicle-stimulating hormone (FSH) or FSH/LH preparations administered continuously at doses ranging from 100 to 225 IU/day before main cohort of follicles reach size 11-12mm | Drug | hCG Protocol |
Primary outcome
Number of oocytes retrieved (oocyte yield)
Time frame: Day of oocyte retrieval (typically 34-36 hours after trigger administration)
The total count of oocytes retrieved following the controlled ovarian stimulation protocol
Proportion of Mature Oocytes (MII Rate)
Time frame: Day of oocyte retrieval
Description: The percentage of retrieved oocytes that have reached the Metaphase II (MII) stage, evaluated according to the standardized ESHRE/ALPHA (Istanbul Consensus, 2025 update) criteria
Fertilization Rate
Time frame: Day 1 following oocyte retrieval
The percentage of mature oocytes (MII) that are successfully fertilized.
Embryo Quality
Time frame: Day 3 and Day 5 following oocyte retrieval
The percentage of good quality cleavage-stage embryos and good quality blastocysts, assessed according to the standardized ESHRE/ALPHA (Istanbul Consensus, 2025 update) criteria.
Total Dose of Gonadotropins/hCG
Time frame: From Day 1 of stimulation up to the day of trigger administration (approximately 10-14 days)
The total cumulative dose in International Units (IU) of gonadotropins or hCG administered throughout the entire stimulation cycle
6 secondary outcomes
Clinical Pregnancy Rate
Time frame: Approximately 4 to 6 weeks following embryo transfer
Live Birth Rate
Time frame: Approximately 9 to 10 months following embryo transfer
Incidence of Ovarian Hyperstimulation Syndrome (OHSS)
Time frame: From the day of trigger administration through the luteal phase/early pregnancy
Average Duration of Stimulation
Time frame: From Day 1 of stimulation up to the day of trigger administration (approximately 10-14 days)
Endometrial Thickness
Time frame: On the day of trigger administration
Cost of Stimulation Protocol per Cycle
Time frame: At the completion of the stimulation protocol (day of trigger)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Background: PubMed 39991766Huong NTL, Thuy TT, Anh PTT, Long HB, Thang LD, Ngoc VT, Do LQ, Duy NXA, Hanh BT, Loi DV, Hoang L. Effects of 100 IU versus 150 IU hCG supplementation on oocyte and embryo quality in patients aged >/= 35 years: a propensity score-matched analysis. Int J Med Sci. 2025 Jan 27;22(4):982-989. doi: 10.7150/ijms.106965. eCollection 2025.
- Background: PubMed 19617207Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study. Hum Reprod. 2009 Nov;24(11):2910-6. doi: 10.1093/humrep/dep253. Epub 2009 Jul 17.
- Background: PubMed 16084880Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005 Aug;84(2):394-401. doi: 10.1016/j.fertnstert.2005.02.036.
- Background: PubMed 36482630Lin H, Huang X, Zhao Y, Wang Y, Wang S, Hong F, Pan M, Liu L. Low-dose human chorionic gonadotropin supplementation initiated at the onset of ovarian stimulation can improve oocyte quality without impairing endometrial receptivity: Case series. Medicine (Baltimore). 2022 Dec 2;101(48):e32175. doi: 10.1097/MD.0000000000032175.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) that underlie the results reported in the final published article will be shared. This includes data collected for the primary and secondary endpoints, after appropriate anonymization to ensure strict compliance with GDPR and Ukrainian data protection laws.
Related trials for Infertility (IVF Patients)
Recruiting
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Recruiting
The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process
Infertility (IVF Patients)
Not yet recruiting
Intra-ovarian CAPA-IVM vs Standard IVM
Infertility (IVF Patients), Infertility
Not yet recruitingObservational study
Endometrial Immune Profile in Recurrent Implantation Failure
Recurrent Implantation Failure, Infertility (IVF Patients)
RecruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Oleksandr O. Plyh, MD principal investigator
LTD "EKODNIPRO"
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Human Chorionic Gonadotropin (hCG), GnRH antagonist and Dual trigger (human chorionic gonadotropin plus GnRH-agonist) in people with Infertility (IVF Patients) and Infertility Assisted Reproductive Technology, run by LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Ukraine, Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of oocytes retrieved (oocyte yield) (time frame: Day of oocyte retrieval (typically 34-36 hours after trigger administration)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07771283, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.